Cannabis-derived THC vs CBD in people with multiple sclerosis
Official title: The Differential Effects of THC vs. CBD on Cognition in Persons With MS
Run by University of Calgary · NCT06261489 · Data updated 2026-11-12
This study tests whether THC or CBD pills affect thinking skills and bladder symptoms in people with MS.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 26 Years to 59 Years |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | University of Calgary Academic / other |
| Locations | 2 sites (Calgary, Alberta and 1 other locations) |
| Status | Recruiting |
| Started | December 5, 2025 |
| Main results expected | September 30, 2027 |
| Study ends | September 30, 2027 |
| Registry record updated | September 15, 2026 |
| Trial ID | NCT06261489 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults 26-59 with confirmed MS and neurogenic bladder symptoms who are on stable NLUTD therapy and willing to adhere to study procedures.
✕Probably not a fit
Patients with recent MS relapse, major psychiatric or neurological disorders, or recent high cannabis use may not benefit and could be excluded.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a Phase 2, randomized, double-blind trial comparing THC and CBD taken orally for 15 weeks in adults with multiple sclerosis and neurogenic bladder symptoms. Participants complete cognitive tests and questionnaires to see how each cannabinoid affects cognitive function and bladder-related symptoms. The trial aims to clarify potential cognitive risks and differences between THC and CBD in this population. Eligibility includes adults 26-59 with MS and NLUTD, stable NLUTD treatment, and consent to participate; exclusions cover major psychiatric or neurological conditions and recent cannabis use. The study is led by the University of Calgary with partner support from the MS Society of Canada, at Calgary sites.
Why it matters
Potential benefit: If successful, results could guide safer use of cannabis-based medicines for MS patients, particularly regarding cognition and bladder symptoms.
How similar studies have gone: Previous cannabis studies in MS have shown mixed cognitive effects; this trial adds direct THC vs CBD comparison in a NLUTD-enriched MS population.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age between 26 and 59 years inclusive. * Confirmed diagnosis of Multiple Sclerosis as per McDonald criteria (any type) \[12\] * Symptoms of neurogenic lower urinary tract dysfunction (NLUTD) as measured by neurogenic bladder symptom score (NBSS), with a minimum score of 7. * If already on a medication for NLUTD, must be stable on this medication for at least 4 weeks. * Sexually active men and women of child-bearing potential must agree to use adequate contraception. * Written informed consent. Exclusion Criteria: * Major psychiatric disorder such as schizophrenia or bipolar disorder * Major neurological disorder which could affect cognition such as dementia, traumatic brain injury. * Seizure disorder * Use of antipsychotic medication * Use of benzodiazepines other than exclusively at night/bedtime * Experienced a MS relapse in the last ninety (90) days. * Current use of cannabis or CBM greater than 3x/week. * Currently using cannabis/CBM less than 3x/week and being unwilling to abstain for the duration of the study. * Visual acuity (binocular) worse than 20/70 (in order to complete the cognitive outcomes) * Significant upper extremity disability that would interfere with the cognitive tests battery. * Indwelling catheter use/urinary diversion * Pregnant or Breastfeeding
Where it's running
-
University of Calgary Foothills Medical Center
Calgary, Alberta, Canada Recruiting -
University of Calgary
Calgary, Alberta, Canada Recruiting
Study contacts
- Study coordinator: Sarah A Morrow, MD, MS, FRCPC, FAAN
- Email: sarah.morrow@albertahealthservices.ca
- Phone: 1-403-9444241
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Treadmill-based virtual reality walking training for MS patients
This study tests whether a treadmill with virtual reality and smart socks can help people with multiple sclerosis walk better and feel safer in daily life.
-
Virtual Reality and Mental Practice to Improve Balance and Walking in Relapsing MS
This study tests whether virtual reality training or mental practice can improve balance and walking in people with relapsing–remitting multiple sclerosis.
-
REAL-MS: A Look at Autologous Stem Cell Transplant vs High-Efficacy MS Therapies in Real-World Care
This study tests how AHSCT compares to high-efficacy MS medicines in adults treated in routine clinical care.
-
Tolebrutinib in real-world MS care for patients treated by clinicians
This real-world study sees how tolebrutinib is used for multiple sclerosis patients and what outcomes look like in everyday practice.
-
Pilates via live video vs. prerecorded videos for people with multiple sclerosis
This study tests whether live, coach-led Pilates sessions through video calls are more beneficial than prerecorded Pilates videos for adults with MS.
-
Cooling During Inpatient Rehab for People with MS
This trial tests whether wearing a cooling vest during intensive training can reduce fatigue and improve walking, strength, balance, and cognition in people with multiple sclerosis during a 3-week inpatient rehab stay.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.